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Abstract: With over 1 million incidence cases and more than 780,000 deaths in 2018, gastric cancer (GC)
was ranked as the 5th most common cancer and the 3rd leading cause of cancer deaths worldwide.
Though several biomarkers, including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9),
and cancer antigen 72-4 (CA72-4), have been identified, their diagnostic accuracies were modest.
Circulating tumor cells (CTCs), cells derived from tumors and present in body fluids, have recently
emerged as promising biomarkers, diagnostically and prognostically, of cancers, including GC. In this
review, we present the landscape of CTCs from migration, to the presence in circulation, biologic
properties, and morphologic heterogeneities. We evaluated clinical implications of CTCs in GC
patients, including diagnosis, prognosis, and therapeutic management, as well as their application in
immunotherapy. On the one hand, major challenges in using CTCs in GC were analyzed, from the
differences of cut-off values of CTC positivity, to techniques used for sampling, storage conditions,
and CTC molecular markers, as well as the unavailability of relevant enrichment and detection
techniques. On the other hand, we discussed future perspectives of using CTCs in GC management
and research, including the use of circulating tumor microembolies; of CTC checkpoint blockade in
immunotherapy; and of organoid models. Despite the fact that there are remaining challenges in
techniques, CTCs have potential as novel biomarkers and/or a non-invasive method for diagnostics,
prognostics, and treatment monitoring of GC, particularly in the era of precision medicine.
Keywords: circulating tumor cells; gastric cancer; diagnostic; prognostic; treatment
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1. Introduction
According to data from the International Agency for Research on Cancer, over 1 million new cases
of gastric cancer (GC) were found in the past year, and GC was determined to be the third highest
cause of cancer-related mortalities worldwide [1,2]. The overall five-year survival rate of GC after
curative surgery is approximately 30%. There is a great variation of GC survival rate from developed
to developing countries [3], as a patient’s prognosis is highly dependent on the stage of the tumor
found during surgery. In areas where endoscopic screenings are regularly conducted, such as Japan,
a significantly high five-year survival rate is achieved due to the increased possibility for early tumor
resection [4]. This survival rate can also drop to less than 5% if the patient is diagnosed at later stages
(IIIB to IV) (https://www.cancer.net/). Reliable screening and early diagnosis, therefore, play a critical
role in the management of GC and patient survival. Despite recent advancement in GC diagnosis and
treatment, prognostic outcomes for patients remain quite poor [5]. The asymptomatic characteristics
at early stages, high recurrent risk, and rapid metastasis after operation are the main problems that
hinder effective diagnosis and treatment of GC.
To date, several biomarkers have been successfully identified and widely used for GC diagnosis
and prognosis, including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer
antigen 72-4 (CA72-4) [5]. However, those biomarkers display less than 40% positivity rates, and their
sensitivities and specificities are modest [5,6]. In this regard, circulating tumor cells (CTCs) emerge
as promising markers to monitor treatment responses and to provide progression information in a
real-time manner [7–10].
CTCs are cells that dissociate from the primary tumor and travel through the vasculature. Prior
studies have shown that in many cases, the spread and migration of CTCs are heavily responsible for
the establishment of distant metastases [11]. CTCs are present in body fluids well before metastasis and
they could potentially be used as a predictive indicator of future metastatic formations [11]. Therefore,
the use of CTCs for cancer screenings is really promising, as the routine profiling and detection
of CTCs from the blood could lead towards the development of a far more efficient, noninvasive
system for detection of tumors. Additionally, CTCs exhibit certain properties and unique molecular
traits of the primary tumor that could provide valuable insights into possible mechanisms of cancer
treatment [12–14].
Currently, CTCs have been approved by the FDA as a prognostic biomarker for monitoring
patients with breast, prostate, and colorectal cancer [15]. However, the clinical utility of CTCs in
GC is still limited. Given the importance of the topic, we performed this review with an aim to
provide an up-to-date, comprehensive picture of CTCs in GC, from a biological standpoint to their
clinical applications. We discussed the challenges and future perspectives of CTC use in the diagnosis,
prognosis, and treatment of GC.
2. Landscape of CTCs
2.1. CTC Migration
The process of CTC migration is critical towards understanding their behavior in circulation. In the
vasculature, CTCs are exposed to attacks from the immune system, high shear stress, and oxidative
stress, which pose severely harsh conditions for CTC survival [16,17]. The vast majority of CTCs fail to
survive in this foreign environment. However, few CTCs are able to survive and contribute towards
the formation of distant metastases, raising the questions of how they are able to do this and what
molecular mechanisms are involved.
The traditional model of CTC migration relies heavily upon the epithelial to mesenchymal transition
(EMT) process. A major defining characteristic of CTCs in the epithelial state is the expression of
e-cadherin, a surface protein heavily involved in the formation of tight junctions and responsible for
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cellular adhesion [18–20]. Consequently, CTCs are inter-locked in a network of intracellular adhesions
and lack of migration capabilities. In their mesenchymal state, however, the cells exhibit far greater
invasive and migratory properties and are less prone to apoptosis. The increased expression of
transforming growth factor β (TGF-β) and several transcriptional factors play critical roles in the
induction of EMT and lead to the downregulation of e-cadherin, along with other epithelial markers
like alpha and beta catenin [21–25]. The overexpression of extracellular matrix (ECM) proteins such as
vimentin and fibronectin results in the induction of certain mesenchymal properties [26,27]. Additional
EMT-induced modifications that are likely to help the CTCs adapt in the harsh microenvironments, such
as the upregulation of cluster of differentiation 47 (CD47) for increased defense against immune attacks
or the downregulation of chaperone calreticulin to dodge immune-surveillance [28]. Further, TGF-β
has been shown to induce increased coagulation, resulting in the formation of a platelet-rich microclot
around CTCs which could physically protect them from the high shear stress in the vasculature as well
as provide shielding from NK-mediated attack [29]. EMT has also been shown to activate survival
pathways such as Akt and P13k signaling to provide resistance to apoptosis [29].
It is noteworthy that after EMT, CTCs are able to invade the blood vessels and lymph capillaries and
migrate towards various organs [30,31]. Once the CTCs are in the vasculature, they can either establish
metastases in distant organs or return to the primary tumor, a process known as self-seeding [16].
Self-seeding contributes towards metastatic development, because due to the leaky neovasculature of
tumors, “self-seeding” CTCs in circulation would not require significant adaptations to infiltrate their
host tumor [32]. Consequently, the host tumor would be enriched with aggressive CTCs that would
lead to an increase in the overall metastatic potential of the tumor. It was found by Kim et al. in a
study of MDA231 mammary tumors in mice that self-seeded tumors had a significant increase in the
rate of tumor growth, along with increased angiogenesis and stromal recruitment [32].
At their target location, CTCs can accomplish infiltration by undergoing a
mesenchymal-to-epithelial cell transition (MET), the reversion of EMT, allowing them to
regain their cellular adhesion [33,34]. Yet, even after observing the various modifications that CTCs
have undergone for migration, our understanding on how individual CTCs are able to survive in
the vasculature and to establish metastases is yet to be elucidated. CTC clusters were generally
ignored as there has been a speculation that their large size would enable them to rupture blood
vessel walls [17,35]. However, CTC clusters have been observed in the peripheral blood, and it
is known that CTC clusters are easier to resist to high shear stress, immune system attacks and
anchorage-dependent apoptosis than individual cells [35,36]. Therefore, the migration of CTCs in
clusters has gained attention as they could have a far greater impact on colonization and metastatic
potential than individual CTCs.
The inner regions of CTC clusters include networks of densely connected cells connected by
cell junctions that express various adhesion molecules, while the cells on the outer regions of CTC
clusters exhibit far greater migratory properties and are receptive to extracellular inputs directing
its migration [30]. Certain received inputs lead to the activation of selected pathways, including
mitogen-activated protein kinase (MAPK), extracellular-signal-regulated kinase (ERK), etc., that result
in leader cell-type selection in certain CTC subsets and inhibition of leader cell-type selection in
the adjacent areas [30]. Unlike individual CTCs, CTC clusters do not completely differentiate from
the epithelial to mesenchymal type. Instead, there exists a spectrum of a hybrid epithelial and
mesenchymal phenotype. It is also suggested that EMT occurred in a morphogenetic manner, as certain
cells in the outer region of CTC cluster tend to lose the majority of their epithelial profile and begin
expressing mesenchymal markers, while follower cells are able to retain most of their epithelial
phenotype [16,37,38].
It is therefore obvious that CTCs have evolved an extensive and nuanced process for migration.
Many of the mechanisms behind the migration of CTCs depend on their highly plastic nature,
which is observed in their adaptation to different phenotypes and characteristics according to their
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microenvironment. Yet, there are still many gaps in our understanding of CTCs migration and thus
further research on this area is warranted.
2.2. CTCs in Circulation
Once CTCs enter the bloodstream, they have the potential to colonize to the distant organs
and establish metastases or return to their primary tumor site(s). However, even with the extensive
modifications they have undergone, most CTCs, whether they are circulating individually or in clusters,
are unable to survive in the hostile environment of the vasculature before they can extravasate into
surrounding tissues [13].
Different studies have demonstrated that the few survivable CTCs which have high metastatic
potential, undergo various mechanisms to prolong survival while in circulation. For instance,
Shliakhtunou et al. [39] found significant overexpression of the survivin gene in all 36 samples of
primary breast carcinoma with malignant tumors compared with benign ones. Moderate and late-stage
tumors, in particular, express survivin at a significantly high level. Survivin suppresses apoptosis
by inhibiting caspase 6 and 8 activation and also provides a defense against NK cell cytotoxicity;
therefore, its overexpression would provide a survival advantage towards CTCs [40]. Cytokines are also
extensively involved with CTCs in the circulation. In a study by Huh et al., human melanoma cells were
injected into mice intravenously [41]. Upon administration of human neutrophils, cancer cell retention
in the lungs and metastatic growth significantly increased in comparison to non-neutrophil treated mice.
Further, the secretion of cytokine IL-8 by melanoma cells attracts neutrophils and promotes B-integrin
expression, which facilitates anchorage of the cells to the vascular endothelium [41]. Additionally,
Divella et al. found that CTC clusters in patients with metastatic colorectal cancer were significantly
associated with elevated levels of cytokines CXCL1 and TGF-beta in circulation [42]. Other studies
have also demonstrated this correlation between elevated production of cytokines and CTCs [43–45].
Taken together, these findings suggest that CTCs exhibit a cytokine-mediated interaction which aids in
CTC survival, transendothelial migration and metastatic development.
It has also been observed that platelet interaction plays an important role in CTC survival.
EMT-mediated platelet coating around the CTC surface provides a shield from natural killer
(NK)-mediated tumor attack as well from the shear and dynamic stress in the bloodstream [46,47].
Furthermore, platelet depletion enhances the efficacy of NK cytolysis of CTCs [48]. Accordingly, Placke
et al. [49] utilized immunoelectron microscopy, immunofluorescent staining, and other techniques to
reveal that platelet coating of CTCs results in the transfer of platelet-derived major histocompatibility
complex (MHC Class 1) to the cell surface of CTCs, allowing them to mimic the phenotype of a host
cell and therefore escape from immunosurveillance. These results suggested that therapies targeting
platelet production may have critical effects in reducing CTC survival and preventing metastasis
formation. Additionally, conditions such as thrombocytosis associated with excessive platelet formation
may be used as prognostic indicators for tumor malignancy and migration, as increased platelet
accumulation stemming from these conditions may help facilitate CTC survival and hence promote
metastatic formation [50].
Overall, in circulation, there are several mechanisms in place to protect CTCs from the harsh
environment of the vasculature. Further understanding these mechanisms could provide valuable
insight into possible therapies that can inhibit the progression of certain tumors.
2.3. Morphologic Heterogeneity of CTCs
A critical property of CTCs are their heterogeneities. CTCs derived from the same tumor exhibit
a wide variety of morphological traits, which include size, ratio of nucleus to cytoplasm, structural
irregularities, and apoptotic phenotype. CTC heterogeneity is largely responsible for its metastatic
capabilities, as greater diversity in CTC morphology allows clonal selection of CTCs at secondary
tumor site [51]. Generally, conventional CTCs that are positive for cytokeratin and EpCAM and
negative for CD45 have a larger size and nucleus-to-cytoplasm ratio than leukocytes [52]. They have a
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distinct cytokeratin signal in the cytoplasm around the nucleus that is larger than the surrounding
white blood cell nuclei [13]. CTCs that have a more mesenchymal phenotype and a reduced EpCAM
expression and cytokeratin signal exhibit a large and irregularly shaped nucleus [13]. Other CTCs may
have a nucleus with no size difference than those of white blood cell (WBC), or they may be apoptotic,
showing a disrupted nucleus and/or possibly cytokeratin stain while also expressing M30, a neoepitope
heavily involved in carrying out apoptosis [13,53]. They may have significant implications in assessing
metastatic potential of tumors in patients. Kallergi et al., using 56 CTC positive patients, demonstrated
that apoptotic CTCs were found under significantly lower amounts in patients that had metastatic
disease [54]. Additionally, they found that the percentage of apoptotic CTCs was lower in patients
with advanced stages of disease compared to patients who had early stages.
CTCs derived from the same tumor exhibit varying morphological and immunophenotypical
characteristics. Given the few examples presented above of CTC heterogeneity, this diversity may have
implications in the use of CTCs to analyze the effectiveness of certain therapeutic strategies for disease
treatment [53].
3. Clinical Implication of CTCs in GC
Although CTCs were discovered 150 years ago, the studies on clinical utilities of CTCs in GC
has peaked recently, particular during the past five years. The systematic review in Table 1 shows
that CTCs have significant values in the diagnosis, prognosis, and treatment management of GC at
various stages.
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Table 1. Systematic Review of the Clinical Significances of Circulating Tumor Cells (CTCs) in Gastric Cancer (GC) in Studies during 2015–2019 Period.
Author, Country,
Year Cases
Isolation and
Identification
Tool
Markers
OS and PFS of
CTC(+) vs.
CTC(-)
Positive Cutoff Clinical Implications Reference
Lee
(South Korea),
2015
100 metastatic GC
patients
anti-EpCAM
antibody coated
magnetic particles
CTC-Profiler
(Veridex)
EpCAM,
CK8/18/19, CD45
OS: 120 days vs.
220 days; p = 0.03)
PFS: 59 days vs.
141 days; p = 0.004
≥ 5CTCs/7.5 mL
CTCs are associated with poor response to
chemotherapy in metastatic gastric cancer patients.
CTC positivity was an independent adverse factor
for PFS and OS.
[55]
Okabe
(Japan), 2016
136 advanced GC
patients
semi-automated
immunomagnetic
separation system
CellSearch
EpCAM,
CK8/18/19CD45,
DAPI
OS: HR 2.20
[95%CI:
1.120–4.03]; p =
0.009 PFS: HR 2.03
[95%CI: 1.13–3.66];
p = 0.016
≥ 1 CTCs/7.5 mL
Detection of CTCs was an independent predictor of
a shorter PFS in advanced gastric cancer.
Patients who require intensive treatment: CTCs
could be a valuable biomarker.
The combined status of CTC and CY would be
useful in selecting patients for radical surgery.
[56]
Zhou
2016
1110 GC patients
in meta-analysis - -
OS: HR = 2.23, 95%
CI: 1.86–2.66
PFS: HR = 2.02,
95% CI: 1.36–2.99
-
High CTCs count was associated with depth of
infiltration regional lymph nodes metastasis and
distant metastasis.
For un-resectable GC patients, high CTCs count
before and during chemotherapy was significantly
correlated with poor OS, PFS, and DC rate.
[57]
Mishima(Japan),
2017
101 GC patients
15 advanced GC
patients whose
primary tumors
were HER2-, but
CTCs were HER2+
both 3 D-IF-FISH
method &
CellSearch
System3D-IF-FISH
only
EpCAM,
CK8/18/19, CD45
HER2
OS and PFS of 15
advanced GC
patients with CTC-
HER2+: 6.1
months (95% CI:
2.1–10.0) and 14.4
months (11.0–17.8),
respectively
≥ 1 CTCs/7.5 mL
New, non-invasive strategy to select patients who
are likely to benefit from trastuzumab-based
therapies, despite their primary biopsy being
HER2-negative.
[58]
Liu (China), 2017 59 GC patients ofstage II-IV
CELLection™
Epithelial Enrich
kit
EpCAM,
CK8/18/19, DAPI
OS: HR = 3.59, 95%
CI:1.655-7.817, p =
0.001
PFS: = 2.81, 95%
CI:1.313-5.999, p =
0.008
≥ 2 CTCs/5 mL
The baseline CTC count of >2 cells/5 mL and an
increase of the CTC count after the first cycle of
chemotherapy was an independent prognostic
marker of poor PFS and OS→ patients with a low
baseline CTC count or decrease of the CTC count
after the first cycle of chemotherapy may benefit
significantly from palliative chemotherapy
[59]
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Table 1. Cont.
Author, Country,
Year Cases
Isolation and
Identification
Tool
Markers
OS and PFS of
CTC(+) vs.
CTC(-)
Positive Cutoff Clinical Implications Reference
Zheng
(China), 2017 81 GC patients ISET-immunofluorescence
CK8/18/19,
vimentin
CTM positivity
was an
independent factor
for determining
the PFS (p = 0.016)
and OS (p = 0.003)
of stage IV patients
CTM correlated
with shorter PFS
and OS than single
CTCs (p < 0.05)
≥ 1 CTCs/5 mL
For CTM: ≥ 3
CTCs
In stage IV patients, CTM positivity was correlated
with serum CA125 level. CTM were an independent
predictor of shorter PFS and OS in stage IV patients.
→ CTM detection may be a useful tool to predict
prognosis in stage IV patients.
[60]
Kang
(South Korea),
2017
116 patients with
gastric cancer
patients & 31
healthy volunteers
“FAST disc”
centrifugal
microfluidic
system
EpCAM,
CK8/18/19, CD45
DAPI
-
≥ 2 CTCs/7.5 mL
Sensitivity: 85.3
Specificity: 90.3
Although the clinical feasibility of CTCs for gastric
cancer staging was not proved, these results suggest
a potential role of CTCs as an early diagnostic
biomarker of gastric cancer.
[61]
Yue (China), 2018
35 patients with
different advanced
gastrointestinal
tumors
Pep
MNPs isolated
system
CK19, CD45 DAPI,
PD-L1
PFS based on
baseline PD-L1high
CTC count: 4.27 vs.
2.07 months HR =
3.342; 95%CI
1.488–7.505; p=
0.002
PFS based on
post-therapeutic
PD-L1high CTC
count: 3.4 vs. 2.1
months; HR=
0.412; 95%CI
0.177–0.962;, p=
0.031)
≥ 2 PD-L1high
CTCs/4 mL
The abundance of PD-L1high CTCs at baseline might
serve as a predictor to screen patients for
PD-1/PD-L1 blockade therapies.
Measuring the dynamic changes of CTC could
indicate the therapeutic response at early time.
[62]
Yang
(China),
2018
40 GC patients
wedge-shaped
microfluidic chip
(CTC-∆Chip) &
three-color
immunocytochemistry
method
(CK, CD45,
Nucleus marker - -
CTC-∆Chip exhibited the feasibility of detecting
CTCs from different types of solid tumor, and it
identified 7.30 ± 7.29 CTCs from 2 mL peripheral
blood with a positive rate of 75% (30/40) in GC
patients.
Novel CTC-∆Chip shows high performance for
detecting CTCs from less volume of blood samples
of cancer patients and important clinical significance
in GC.
[63]
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Table 1. Cont.
Author, Country,
Year Cases
Isolation and
Identification
Tool
Markers
OS and PFS of
CTC(+) vs.
CTC(-)
Positive Cutoff Clinical Implications Reference
Li (China), 2018
115 advanced GC
patients, including
56 tumor HER2+
subjects who
received first-line
HER2-targeted
therapy plus
chemotherapy and
59 tumor HER2−
subjects who
received
chemotherapy
alone
IF-FISH Cytelligen
system
DAPI, HER2,
CEP8, and CD45 - -
CTC HER2+ was found in 91.0% of tumor HER2+
and 76.2% tumor HER2− patients and was
correlated with development of resistance to
trastuzumab for the tumor HER2+ patients and
chemotherapy alone for the tumor HER2− patients.
Determining of CTC HER2 showed advantages in
real-time monitoring of therapeutic resistance.
[64]
Cheng (China),
2019
32 advanced GC
patients
CanPatrol CTC
enrichment
technique
Multiplex RNA in
situ hybridization
assay
EpCAM,
CK8/18/19, CD45
DAPI, PD-L1,
Vimentin and
Twist
- ≥ 2 PD-L1
+
CTCs/5 mL
CTCs count was well correlated with
clinicopathology parameters.
Enumeration of epithelial CTC subset and its
relative abundance in the total CTC pool are highly
correlated with clinical efficacy.
Monitoring CTC subtypes exhibits higher sensitivity
of evaluating the disease status, compared to the
traditional methods.
[65]
Lu
(China), 2019
42 GC patients of
stage III-IV
ISET-ICC method
followed by IHC
EpCAM,
CK8/18/19, CD45,
Vimentin and
Twist, E-cadherin
- -
The threshold number of CTCs is significantly
associated with different clinical stages and was
positively correlated with the value in U/mL of
CA724.
CTCs technology based on ISET method has a high
detection rate.
CTCs are promising predictor for the evaluation and
prediction of treatment responses in stage III–IV
gastric cancer.
[66]
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Table 1. Cont.
Abdallah
(Brazil), 2019
At diagnosis (55
samples before
neoadjuvant
treatment)
After surgery and
before adjuvant
therapy (33
samples)
ISET and
immunocytochemistry
& microscopy
HER2 and
plakoglobin, CD45
-PFS between
CTM-positive
patients vs.
CTM-negative
patients (18.7
months vs. 21.6
months; p = 0.258
-PFS between
plakoglobin-positive
CTM patients vs.
plakoglobin-positive
CTM patients: 15.9
months vs. 21.3
months; p= 0.114
≥ 1 CTM (2
CTCs)/4 mL
The analysis of CTM plakoglobin expression is a
promising tool in the understanding the biology and
prognosis of GC.
[67]
Gao, 2019 3814 GC patientsin meta-analysis - -
HR = 1.84, 95%CI
1.50–2.26, p < 0.001 - CTC positivity was associated with poorer OS. [68]
CellSearch: semi-automated immunomagnetic separation system; CTM: circulating tumor microembolies; FISH: fluorescent in situ hybridization; IF: immunofluorescence; ISET: isolation
by size of epithelial tumor cells; ICC: immunocytochemistry; IHC: immunohistochemistry; OS: overall survival; PFS: progression-free survival.
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3.1. Diagnostic Potential of CTC in GC
Similar to other types of cancer, early detection is one of the most important challenges to GC
since 80% of patients are asymptomatic during the early stages [69]. Recently, the role of CTCs in
GC diagnosis has markedly gained attention. A meta-analysis by Tang et al. [70] recommended that
CTC detection alone could not be used for GC screening because of poor sensitivity. However, with a
high positive likelihood ratio and especially the specificity of 0.99 and the area under the curve (AUC)
of 0.97 in the receiver operating characteristic (ROC) curve, CTCs detection could be useful for the
confirmation of GC. Intriguingly, also according to Tang et al. [70], from 1997 until 2012, there was an
annually increased trend of sensitivity, suggesting that the advancement in detection technology might
help improving the diagnostic accuracy of CTCs. Indeed, using a centrifugal microfluidic system with
a new fluid-assisted separation technique, Kang et al. [61] showed that the sensitivity and specificity of
CTCs in GC detection were 85.3% and 90.3%, respectively. A cut off ≥ 2 CTCs per 7.5 mL of blood was
useful for differentiating GC patients from healthy controls.
In addition to CTC enumeration, CTC molecular profiles can be used for GC diagnosis as well.
A combination of cytokeratin 19 and 20 from CTCs can detect GC with sensitivity and specificity of 87.5%
and 94.7%, respectively, suggesting their use in the diagnosis of GC [71]. Recently, miRNAs are emerging
as biomarkers in diagnosis and treatment of cancers in general and GC in particular [72,73]. A number
of miRNAs from peripheral mononuclear cells could be used as surrogate markers to highlight GC
patients. For instance, the ROC-AUC obtained with miR-421, a miRNA which is overexpressed in GC,
targeting E-cadherin and caspase-3, thereby enhancing metastasis and attenuating apoptosis [74], is 0.77,
with a positive detection rate of 72.5%, much higher than that of CEA, one of the most conventional
tumor markers. A cut-off value of 7.075 is applied for miR-421 to detect GC [75]. Similarly, several
oncogenic proliferation-triggering miRNA such as miR-543 [76] targeting Sirtuin 1 (SIRT1), miR-106a
targeting tissue inhibitor of metalloproteinases 2 (TIMP2) [77], or miR-17 which targets a number of
genes involving in tumorigenesis, disease progression, invasion, and metastasis of GC [78,79] have
been suggested as candidate markers for GC diagnosis.
3.2. CTC Assay for Prognosis and Treatment Management of GC
In spite of advances in surgery in combination with chemo-radiotherapy in GC management,
metastasis and relapse are still of great concern. Relevant assessment of malignant stages and prognosis
are important to the success of such regimens. A meta-analysis on 2566 GC patients from Asia,
Europe, and Africa showed a significant correlation between the detection incidence of CTCs and
clinico-pathological parameters, including cancer stages, vessel and lymphatic invasion, and tumor
histological differentiation. Moreover, there was a correlation between CTCs and disease-free survival
(DFS) (hazard ratio—HR = 3.42, 95% confidence interval-CI: 2.39–4.91) as well as the overall survival
(OS) (HR = 2.13, 95% CI: 1.13–4.03). Such results support the potential of using CTCs as a prognostic
indicator in GC [80]. Similarly, in the study by Zheng et al. [56], positive CTC counts were more
common for tumors with diffuse histologic type and distant metastasis, followed by significantly
shorter progression-free survival (PFS) (HR = 2.03, p = 0.016). Accordingly, CTCs can be used as a
biomarker for considering patients who need intensive treatment (Figure 1).
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Figure 1. The predictive utility of CTCs in gastric cancer treatment. High baseline or acquired CTCs 
count was associated with decreased OS, PFS, and DC. The HER2 and PD-L1 positivity or high 
amplification could predict positive response to trastuzumab and checkpoint therapy, respectively. 
Meanwhile, the CD44+ CTCs were associated with poor prognosis and metastasis. 
Additionally, in a study by Li et al. [81], the post-therapy CTC level was used for monitoring 
therapeutic response in GC patients and predicting their prognosis. Following 6 weeks of 
chemotherapy, an unfavorable CTC count (≥ 3 CTCs per 7.5 mL) significantly correlated with the 
objective response rate (p = 0.02) and the disease control rate (p = 0.01) and furthermore could 
independently predict a shorter PFS and OS. In contrast, a continuously favorable CTC count or an 
early shift into a favorable CTC count following therapy could predict an improved prognosis. 
Similarly, in Liu’s report [59], only those patients with a low baseline CTC level or a decreased CTC 
level after the first cycle of chemotherapy remarkably benefited from the treatment. Those with a 
baseline CTC level of > 2 cells/5 mL blood, which was determined as an independent poor prognostic 
marker for PFS and OS, were spared from the adverse reactions of chemotherapy. The role of CTC 
count in the prognosis and prediction of chemotherapeutic response was also supported in metastatic 
GC patients [55]. In chemotherapy, not only can CTC count be used to predict recurrence risk after 
operative therapy, there is also a significant difference in the recurrence rates of those patients with 
different preoperative and postoperative CTC levels. A cut-off value of 1 CTC/7.5 mL was chosen for 
CTC measurement. Advanced GC patients with preoperative CTCs ≥1 and increased postoperatively 
had the poorest prognosis [82].  
It should be noted that, not only the number of CTCs but their genotypes and phenotypes can 
affect the prognostic significance in GC (Figure 1). Szczepanik et al. [83] demonstrated that among 
the cytokeratin positive CTCs, only those with CD44+ phenotype were correlated with poor 
prognosis and metastasis. CD44 is a transmembrane glycoprotein that was one of the first molecules 
identified on GC stem cells and is now known to be a marker for cancer stem cells (CSCs) [84]. The 
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Yuan et al. [85]. Moreover, in an in vitro screening by Yuan et al. [85], such CTCs were found to be
relatively sensitive to 5 fluorouracil, cisplatin, and paclitaxel, but relatively resistant to radiation,
oxaliplatin, cetuximab, and trastuzumab. Along with the fact that CD44( + )/CD45(−) CTCs show some
degree of chemotherapy resistance, they have also been shown to exhibit other characteristics of cancer
stem cells (CSC). For example, Grillet et al. generated ex vivo CTC cell lines and found that they
were able to differentiate into distinct heterogenous lineages, indicating the presence of multipotent
cell population resembling CSCs. Additionally, they also found significant expression of CD44 and
aldehyde dehydrogenase, a CSC marker, in CTC cell lines. This indicates that CD44(+)/CD45(−) CTCs
functionally resemble or potentially are CSCs. Therefore, CTCs can mimic the genetic features of
tumors at a given time and represent the current state of disease [86]. CTCs cultured in vitro can
be used for drug sensitivity screening, a promising approach toward precision medicines. The idea
of using CTC culture like an antibiogram has also been raised with other kinds of cancers, such as
advanced metastatic colorectal cancer or breast cancer [87,88].
In precision medicine, patient stratification is essential to select those who respond to a treatment
regimen. The response indicators are usually molecular biomarkers in biopsy samples from primary
tumors. For instance, HER2 upregulation in primary tumors has been used as a biomarker for
personalization of trastuzumab, a HER2 monoclonal antibody in advanced GC [89,90]. Intriguingly,
Mishima et al. [58] recently demonstrated that HER2 amplification in CTCs was found even in
advanced GC patients with HER2 negativity in tumor biopsy. Those patients received clinical benefits
from trastuzumab which were comparable to those from the trastuzumab in combination with
chemotherapy of the ToGA clinical trial [90]. Similarly, as reported by Abdallah et al. [67], three out
of five nonmetastatic gastric adenocarcinoma patients with disease progression had HER2-negative
primary tumors but HER2-positive CTCs. A significant CTC count drop in follow-up was seen for
CTC-HER2-positive cases and CTC-plakoglobin-positive cases compared with CTC-HER2-negative
cases and CTC-plakoglobin-negative cases.
Genetic signatures of CTCs could reveal the metastatic capability and the malignancy of the
cancer cells [14,91]. Mimori et al., using microarray analysis and RT-PCR on 810 GC patients, identified
membrane type 1 matrix metalloproteinase (MT1-MMP) as a marker in CTCs for metastatic growth [92].
Further, Li et al. profiled CTCs in 31 patients with advanced GC [93] found that those with greater
percentages of aneuploid CTCs had significantly poorer progression-free survival and overall survival.
Similarly, Li et al. in karyotyping CTCs from patients with advanced GC found that those with
chromosome 8 aneuploidy CTCs displayed decreased sensitivity and increased resistance to paclitaxel-
and cisplatin-based therapy [94]. Such findings open a perspective of using CTCs as an alternative
biopsy which is less invasive and more effective than the conventional tumor biopsy for GC prognosis
and therapeutic management.
3.3. The Role of CTCs in GC Immunotherapy
With several recent breakthroughs, immunotherapy is an important facet in the improvement of
GC management. Until now, the two major approaches of immunotherapy that have been applied
in GC clinical trials are adoptive cell immunotherapy and immune checkpoint inhibitor use [95].
The immune checkpoint blockade is progressing more rapidly with a promising response rate from
pembrolizumab, a programmed cell death-1 (PD-1) inhibitor, in advanced GC patients [96]. Now,
PD-L1 is the most common biomarker for PD-1/PD-L1 checkpoint blockade therapies. The FDA has
approved four immunohistochemistry (IHC)-based assays for predicting therapeutic responses to
PD-1/PD-L1 blockers. Nonetheless, the predictive value of PD-L1 IHC is still controversial, since in
various types of cancer, including GC, some patients with PD-L1 negative tumors also respond to
anti-PD-1 therapy [96,97]. Recently, Cheng et al. [65] found that in GC patients with negative PD-L1 in
tumor tissue, the CTC Imaging flow cytometry signal was as varied as that of IHC staining, suggesting
that expression of CTC PD-L1 is useful in the immunophenotypic differential diagnosis of tumors and
thus can be a potential candidate for anti-PD-1/PD-L1 immune checkpoint therapy [98]. CTC level
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after checkpoint blockade therapy may be effective to predict poor prognosis in advanced GC [99].
When CTC PD-L1 has been recognized as a biomarker for therapeutic efficacy of immune checkpoint
inhibition in non-small cell lung cancer (NSCLC), it is unclear whether it can be a predictive marker for
GC immune checkpoint therapy [100,101]. Along this line, Yue et al. [62] demonstrated that PD-L1
level in CTCs can be a potential predictor for PD-1/PD-L1 blockade therapies in patients with advanced
gastrointestinal tumors. The disease control (DC) rate in the patients with high CTC PD-L1 level was
much higher than those with lower level. Additionally, several PD-L1 high CTCs at the baseline had
predictive values for PFS. Moreover, the dynamic changes of PD-L1 positive CTCs can reflect real
time response status. Indeed, in Yue’s study [62], the count changes of total CTCs, PD-L1 positive
CTC, and PD-L1 high CTC significantly correlated with the clinical outcomes (Figure 1). This is an
advantage of CTC PD-L1 over tumor PD-L1, which can only provide baseline information for treatment
response prediction. Similarly, Cheng et al., using the CanPatrol CTC enrichment technique to validate
the blood samples from 32 GC patients, also demonstrated that total CTC pool and CTC-PD-L1 are
highly correlated with clinical outcome of checkpoint blockade therapy. In addition, high circulating
PD-L1 expression in advanced GC patients is predictive of better five-year OS [102]. Altogether,
these evidences support CTC PD-L1 expression as a prognostic factor for checkpoint blockade therapy
efficacy. Moreover, recent advances in -OMICs technologies to support single-cell molecular profiling
of CTCs and tumor cells using next-generation sequencing may also provide the pool of tools to
validate predictive biomarkers including CTC PD-1 and PD-L1.
4. Challenge and Future Perspective
4.1. Challenge
Despites promising perspectives of using CTCs as one type of liquid biopsy for GC diagnosis and
prognosis, there are still remarkable challenges for translating them into clinical practice. Notably, there
are controversies on the cut-off value of CTC positivity, since a wide range of CTC levels have been
used in various studies [55,61,81,82]. Critical reasons for this include the unavailability of consensus
in technical approaches ranging from sampling, storage conditions, and CTC molecular markers,
along with a lack of relevant enrichment and detection techniques. To date, most of widely used CTC
detection technologies, including the FDA-approved technology CellSearch, are based on epithelial
markers (i.e., EpCAM, cytokeratins) and epithelial cell surface-associated glycoproteins (i.e., MUC-1)
along with the absence of a leukocyte marker CD45. CTCs are, however, heterogeneous, especially
in metastasis; as a result of EMT, more malignant CTCs with greater mesenchymal phenotypes have
been found. Hence, it is difficult to detect the CTCs with mesenchymal phenotypes by the current
technologies [103]. It is thus essential to develop better technologies which can detect a wide range of
markers for various CTC subpopulations.
4.2. Future Perspective
The current clinical utility of CTCs in GC is limited compared to broad perspectives of using
such non-invasive biopsy for an insight of tumor, thereby leading to new approach of GC diagnosis,
prognosis, and treatment.
The major challenge in CTCs research and application is their precise detection and enrichment.
There have been considerations on the advantages and disadvantages of single cell-analysis of CTCs
over the tumor-derived cell-free DNA (cfDNA) in clinical application. The latter is more stable, easier
to be isolated from blood and analyzed but requires an advance knowledge of the targets of interest,
and its source cannot be clearly defined [104]. Therefore, a simultaneous analysis of both CTCs and
cfDNA would enable better clinical significance. In fact, Keup found no difference of cfDNA isolated
from whole blood and that from CTC-depleted blood, suggesting a solution of combined analysis [105].
On the other hand, the challenge of CTC single cell analysis could be attenuated by detecting CTC
clusters or circulating tumor microembolies (CTM) instead of single CTCs. Using isolation by size
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of epithelial tumor cells (ISET), a technology based on differences in the size and shape of cancer
cells and normal blood cells, Zheng et al. [60] efficiently detected CTCs/CTM in GC patients. CTM
positivity, which was correlated with serum CA125 level, was an independent predictor of PFS and
OS of stage IV patients. Given the stronger metastasis capability of CTMs over CTCs, CTMs can be
developed into not only prognostic biomarkers, but also as therapeutic targets for anti-metastasis
treatment. Recently, a new microfluidic chip for sorting and capturing single CTCs and CTMs has been
demonstrated by Kulasinghe et al. [106], which is a promising new development in CTC/CTM utility.
Another current approach involves using CTCs as a treatment target. Tumor metastasis is initiated by
a CTC subpopulation which escaped from immune surveillance [107]. The expression of a number
of immune checkpoints contribute essentially to the immune-editing capability of the CTCs. Thus,
simultaneous blocking of those CTC checkpoints can be an immunotherapeutic approach. In fact, Lian
et al. have succeeded in targeting both PD-L1 and CD47 on CTC surface, resulting in significantly
lessened tumor growth and metastasis [108].
So far, there is a difference between the results of in vitro drug screening on cancer cell lines and
the in vivo clinical efficacy. The lack of high throughput models with similarities to human cancer
pathology leads to the low success rate of drug discovery in oncotherapy [109]. Recently, an emerging
direction is using organoids to create novel cancer models, which would better resemble the real
tumor both genotypically and phenotypically. Organoids are derivatives of 3D cancer cell culture
including architectural and physiological similarities with the native tumor. The in vitro and in vivo
cancer models using organoids can bridge the traditional preclinical models and clinical trials with the
advantages of being less time-consuming, more economic, and more effective [110]. Seidlitz et al. [111]
generated human and mouse GC organoids which modeled typical characteristics and altered pathways
of human GC. These models revealed valuable information on the native tumor which can be used
for drug screening and biomarker identification, thereby enabling precision medicines. In this
direction, the idea of using CTC-derived organoids instead of tumor-derived organoids is tempting
because of the advantages of real-time monitoring and a non-invasive nature. Bartucci et al. [112]
described an interdisciplinary protocol to develop patient-derived organoids by using chimeric antigen
receptor T cell (CAR-T) immunotherapy. Such an approach of patient specific therapy that targets
cancer vulnerabilities, when combined with anti-proliferative and immunotherapeutic regimens,
could fortify the power of cancer precision medicine. Another perspective in personalized medicine
with immunotherapy is the application of microsatellite instability (MSI) analysis of CTCs. High MSI
tumors which are associated with germline mutation in mismatch repair genes account for about
22% of GCs [113]. Advanced GC patients with high MSI had positive responses to pembrolizumab
(ORR 85.7%) [114]. Although MSI analysis on GC CTCs has not been reported, Steinert et al. found
mutational profiles of CTCs in colorectal cancer patients similar but not identical to the primary tumor
tissue. Despite the mutation of some key genes such as KRAS or TP53 was not identified in the tumor,
they were detectable in CTCs [115]. Such findings suggest a study on association of the high MSI CTCs
with checkpoint immunotherapy response in GC.
One remaining question is whether there is a difference between molecular characteristics of
CTCs derived from primary gastric tumor and those of various organ metastases-derived CTCs.
Such information would be very useful for early detection of micro-metastasis and making rational
treatment decisions in metastasis GC. In a similar way, a unique “CTC gene signature”, which is distinct
from primary breast tumor and involves in signaling pathways associated with breast cancer brain
metastasis (BCBM), was found by Boral et al., suggesting new application of CTCs in management of
BCBM [116].
5. Conclusions
Despite the extensive efforts in improving GC treatment, therapy resistance remains a great
challenge. One of the potential solutions to this problem is liquid biopsy, a less invasive tool which can
provide real-time insights into the tumor. Various blood-based surrogate markers including circulating
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DNA, miRNA, extracellular vesicles, platelets, and CTCs have been studied for liquid biopsy in order
to predict responders to a certain therapy [50,117]. Among these, CTCs, with their newly discovered
clinical significance, could contribute additionally to the perspective of cancer precision medicines
from prognosis to real-time monitoring, therapeutic targets, and drug discovery (Figure 2).
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